Replies to post #16547 on Celsion Corporation (CLSN)

[Biobonic]

From the 3Q CC 2019 comes this statement:

RE: The OPTIMA Phase 3 study: We’ve also said that there is a higher probability of success at the second interim analysis, now anticipated by June of next year, just 7 or 8 short months from now. We stand by that guidance.

From the March 2020 Corp Presentation.

OPTIMA Study, a global Phase III trial in HCC/Primary Liver Cancer, with 2nd interim data expected in early 3rd Quarter of 2020

Hmmm, It appears that it is taking longer than first thought. That is a good thing, when people live longer in a trial that measures how long participants live...